# Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes

> **NCT01617135** · PHASE2 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** CVT-301
- **DRUG:** Placebo
- **DRUG:** Sinemet (carbidopa/levodopa)
- **DRUG:** CVT-301

## Key facts

- **NCT ID:** NCT01617135
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617135, "Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01617135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*